Drosianne

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drosianne

Drosianne is a prescription-only medication, clinically recognized as a combined oral contraceptive (COC), designed exclusively for the prevention of pregnancy. This pharmaceutical preparation is administered as an oral tablet and functions as a synthetic combination product, utilizing two active hormonal substances to regulate the female reproductive cycle.

Property Description
Active ingredients Drospirenone and Ethinyl Estradiol
Form Oral Tablets (Active and Inert variants)
Pharmacological class Hormonal Contraceptives for Systemic Use
Common use Contraception (Pregnancy Prevention)
Origin Synthetic Hormones

What Type of Medication is Drosianne?

Drosianne belongs to the Hormonal Contraceptives for Systemic Use pharmacological group, containing both a synthetic estrogen and a synthetic progestin. This classification reflects its role as a reversible, systematic method for cycle management and pregnancy prevention in women of reproductive potential. Its fixed-dose combination ensures a consistent approach to hormonal contraception.


Composition: Is Drosianne Synthetic Estrogen and Progestin?

The core of Drosianne consists of the synthetic estrogen Ethinyl Estradiol and the unique synthetic progestin Drospirenone. The structure of Drospirenone is a primary differentiating factor, as it is an analogue of spironolactone and exhibits anti-mineralocorticoid and antiandrogenic activity. The inclusion of Drospirenone provides a distinct pharmacological profile; consequently, the drug possesses properties beyond typical progestational effects.


General Purpose: What is Drosianne Used For?

The singular, overriding therapeutic purpose of Drosianne is the prevention of pregnancy. It achieves this high-efficacy goal primarily through the suppression of ovulation, which halts the monthly release of an egg. This action is reinforced by secondary effects that alter the cervical mucus and modify the uterine lining, creating an environment that is reliably unsuitable for conception.

What side effects are possible with Drosianne?

Possible Side Effects and Safety Information

Adverse reactions associated with Drosianne are classified by regulatory bodies based on their documented frequency and the physiological systems affected.

Commonly Documented Adverse Reactions

The most frequent adverse reactions, often listed as Very Common (ge 10%) in clinical data, include headache and breast pain/discomfort. Reactions classified as Common (1% to <10%) include nausea, depression or depressive mood, weight gain, and irregular uterine bleeding (spotting or breakthrough bleeding), which is often noted as more frequent during the first few cycles of use.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents emphasize the potential for serious, low-frequency events, categorized primarily under Vascular and Metabolic Disorders:

  • Thromboembolic Risk: The major documented serious risk is the occurrence of Venous and Arterial Thromboembolic Events (VTE/ATE), such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. Regulatory labeling notes that the risk of VTE may be highest during the first year of use.
  • Hyperkalemia Risk: Due to the anti-mineralocorticoid activity of drospirenone, the potential for hyperkalemia (elevated potassium levels) is a specific documented safety constraint, particularly in high-risk patients.

Population-Specific Restrictions

Official labeling mandates specific contraindications for certain patient populations to mitigate serious risks:

  • The medication is contraindicated in women over 35 years of age who smoke due to a significantly increased risk of serious cardiovascular events.
  • It is also contraindicated for women with pre-existing conditions that predispose to hyperkalemia, specifically renal impairment, hepatic impairment, and adrenal insufficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents provide clear guidance regarding overdosage of Drosianne, a synthetic combination product containing drospirenone and ethinyl estradiol.

Documented Manifestations and Serious Risk

Documented clinical manifestations of overdose primarily include symptoms that are typically not life-threatening. These may involve nausea and vaginal bleeding (often described as withdrawal bleeding).

However, the progestin component, drospirenone, carries an anti-mineralocorticoid effect which dictates the primary serious risk in an overdose scenario: the potential for hyperkalemia (elevated serum potassium concentrations). This physiological effect is a critical consideration in management.

Immediate Emergency Action Required

Upon recognition of an intake exceeding the prescribed dose, immediate emergency medical attention must be sought. Official guidance mandates contacting a Poison Control Center or Poison Help line without delay. Treatment for overdose is strictly symptomatic and supportive, as no specific antidote is known.

Monitoring and At-Risk Populations

Due to the risk of hyperkalemia, overdose management requires the monitoring of serum potassium concentration. Furthermore, the regulatory prescribing information identifies specific populations at an increased risk for adverse outcomes: those with pre-existing renal impairment, hepatic impairment, or adrenal insufficiency.

Therapeutic Uses of Drosianne

Drosianne is indicated for three main therapeutic uses.

Drosianne is applied across domains involving long-term prevention and the management of specific recurrent or inflammatory symptoms, primarily addressing three distinct categories of conditions: systematic pregnancy prevention (contraception), the management of Premenstrual Dysphoric Disorder (PMDD), and the symptomatic relief for moderate acne vulgaris.

The primary therapeutic benefit is the provision of systematic pregnancy prevention. Beyond this, the medication is commonly used to help ease the distressing symptoms of PMDD—a condition marked by recurrent mood disturbances (such as marked irritability and anxiety) and physical discomfort (like bloating and fluid retention)—that may contribute to functional strain. Furthermore, it is applied in addressing the symptomatic management of moderate acne, providing support that helps ease the overall symptom load related to skin manifestations.

“This medication is considered relevant for easing symptoms that interfere with daily comfort across multiple domains, supporting patients during episodes of heightened discomfort.”


Quick Fact: Relief for PMDD and Acne

Domain Symptom Cluster Addressed
PMDD Recurrent, disruptive mood changes (e.g., anxiety, irritability) and physical discomfort (e.g., bloating).
Dermatology Inflammatory lesions, papules, and pustules associated with moderate acne vulgaris.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Drosianne (Drospirenone and Ethinyl Estradiol) is approved for use in females of reproductive potential for contraception, and in post-menarcheal females for moderate acne or PMDD, provided they choose an oral contraceptive. Eligibility is strictly governed by medical criteria detailed in official prescribing information.

Population Status Eligibility Rule (Official)
Absolutely Contraindicated Females over age 35 who smoke; individuals with a history of or current blood clots (DVT/PE), stroke, coronary artery disease, or other thrombotic disorders.
Organ/Metabolic Contraindicated Individuals with Renal Impairment, Adrenal Insufficiency, or active Liver Disease/Tumors.
Hormone-Sensitive Contraindicated Current diagnosis of, or history of, Breast Cancer; also contraindicated in pregnancy.
Age-Related Restrictions Not Indicated for pre-menarcheal girls or for the geriatric/postmenopausal population.

Use is also prohibited in patients with uncontrolled hypertension, diabetes with vascular damage, or migraines with focal neurological symptoms. Use while breastfeeding is not recommended as hormones may pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe two primary mechanisms for drug interactions involving this product: those affecting drug levels and those affecting serum potassium.

  • Interactions Affecting Drug Levels: The efficacy of this medicine can be compromised when taken with agents that induce certain liver enzymes (primarily CYP3A4), such as certain anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital) and antibiotics (e.g., rifampicin). These enzyme inducers may reduce the plasma concentrations of the hormonal components, which can lead to a loss of efficacy. Conversely, strong inhibitors of CYP3A4 (e.g., ketoconazole) may increase the plasma concentration of the product's components, which requires monitoring.

  • Interactions Increasing Serum Potassium: The progestin component, drospirenone, possesses antimineralocorticoid activity. Due to this effect, its use with other medicines that can increase serum potassium, such as potassium-sparing diuretics, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-II receptor antagonists, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or potassium supplements, requires caution. In patients at high risk for hyperkalemia (e.g., those with renal impairment, hepatic impairment, or adrenal insufficiency), this combination is generally not recommended or requires frequent serum potassium monitoring during the first treatment cycle.

  • Food and Herbal Products: Official labeling identifies the potential for grapefruit juice to increase the plasma concentrations of the hormonal components through inhibition of the same metabolic pathway (CYP3A4).

Mechanism of Action

Drosianne (drospirenone) is a synthetic progestin that exhibits multi-receptor engagement, acting as an agonist at the progesterone receptor (PR), and as an antagonist at the mineralocorticoid receptor (MR) and the androgen receptor (AR).

At the PR, Drosianne modulates gene transcription within the hypothalamus and pituitary gland, leading to the suppression of gonadotropin release, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This upstream suppression prevents the physiological events required for ovulation.

In the uterus, PR agonism alters the endometrial lining's morphology and function, and modifies the physical properties of cervical mucus.

As an MR antagonist, Drosianne competes with the endogenous mineralocorticoid aldosterone in the distal renal tubules, reducing the reabsorption of sodium and water. This molecular interaction results in an increase in sodium and water excretion, leading to a subsequent decrease in plasma volume and a potential shift toward hyperkalemia.

In androgen-sensitive tissues, AR antagonism inhibits the binding of endogenous androgens, thereby reducing androgen-mediated cellular signaling and resulting in system-level modulation of pilosebaceous unit activity.

Dosage and Administration Information

Administration Guidelines

Drosianne is administered through the oral route as part of a continuous 28-day cyclic regimen. The standard administration involves taking one tablet once daily at the same time every day, a practice utilized for maintaining consistent hormone levels throughout the cycle. The use pattern is strictly sequential; tablets are taken following the order designated on the blister pack, which guides the transition through the active hormone-containing tablets and the subsequent hormone-free (inert) period.

The active component strength typically contains 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol, often administered in a regimen featuring 24 days of active tablets followed by 4 inert days. The medication may be taken with or without food, and is commonly taken after the evening meal or at bedtime.

Procedural and Population Constraints

Specific procedural steps and constraints apply to the administration of this medication. A non-hormonal barrier method is used for the initial 7 consecutive days of the first cycle if the start date does not align with the first day of the menstrual period. If a single active tablet is missed, the standard procedure is to take it as soon as remembered, even if this results in taking two tablets simultaneously.

The medication is generally used in females of reproductive potential, including those aged 14 years and older. Furthermore, the use of this medication is restricted in populations with renal impairment, hepatic impairment, or adrenal insufficiency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drosianne


Evidence for use in Systematic Pregnancy Prevention (Contraception)

Research primarily was evaluated in large-scale, controlled trials of healthy women requesting protection against pregnancy. Studies monitored the incidence of pregnancy and patterns related to cycle control. Findings describe patterns observed in the studies related to measured pregnancy rates and specific cycle patterns.

Evidence for use in Premenstrual Dysphoric Disorder (PMDD)

Drosianne was studied for its use in conditions involving periods of heightened symptoms, specifically PMDD. Research examined changes in outcomes related to systemic or functional imbalance using standardized scales. Findings describe patterns observed in trials where symptom scores were observed to change in the study populations. It was observed in some studies that patients receiving the placebo also described similar patterns of change. Follow-up durations were limited (primarily three months), and certainty remains low regarding outcomes over many cycles.

Evidence for use in Moderate Acne Vulgaris

The medicine was evaluated in females with moderate facial acne vulgaris who also desired contraception. Studies monitored changes in the number of skin lesions and assessed overall skin appearance. The findings describe patterns observed in the studies related to observed changes in the average count of lesions during the study period. Data for certain groups remain insufficient, as the pivotal trials primarily concentrated on facial lesions.


Areas Where Research Remains Limited

Evidence highlights what is known—and what is still uncertain. Comparative evidence is lacking regarding how Drosianne outcomes compare to other similar treatments, as the primary pivotal trials focused on comparison against a placebo. Long-term effects are not fully established for maintaining non-contraceptive outcomes over many years. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. FDA Approved Patient Labeling Guide for Using Drospirenone and Ethinyl Estradiol Tablets (Contraception, PMDD, Acne Indications)
  2. Acne Vulgaris | Study 91231: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women with Moderate Acne Vulgaris (Pivotal Trial)

Frequently Asked Questions (FAQ)

Common questions about Drosianne (FAQ)


Q: What is the main difference between Drosianne and other drugs for the same condition?

A: Drosianne is a progestin that is described in official documents as having three distinct activities. Beyond its primary progestogenic action of preventing ovulation, it also has anti-mineralocorticoid effects and anti-androgen effects. This combination of documented activities sets it apart from some other hormonal contraceptives.

Q: Are there any long-term effects of taking Drosianne that I should know about?

A: Official labeling details that the risk of serious blood clots (VTE) is highest during the first year of use. Furthermore, evidence supporting the effectiveness for non-contraceptive uses, such as PMDD or acne, over many years remains limited. These constraints are detailed in the official safety warnings.

Q: How quickly does Drosianne start working after I take the first pill?

A: For pregnancy prevention, if the regimen is not started on the first day of the menstrual period, a non-hormonal barrier method is advised in official guidelines for the initial seven consecutive days of the first cycle. This non-hormonal barrier method use is advised to ensure consistent drug levels are maintained at the start of treatment.

Q: Can Drosianne interact with common over-the-counter pain relievers?

A: Regulatory documents caution that certain non-steroidal anti-inflammatory drugs (NSAIDs) may increase the potassium levels in the blood when taken with Drosianne. This specific risk requires caution when these drug types are used by patients at risk, such as those with kidney or liver issues.

Q: Do the side effects of Drosianne get better over time?

A: Irregular uterine bleeding, such as spotting or breakthrough bleeding, is documented in clinical studies as being more frequent during the first few cycles of use. This pattern is documented in studies as often resolving with continued use, as the body adjusts to the medication.

Q: Why do doctors check certain blood levels before starting Drosianne?

A: The check is primarily related to the drug's anti-mineralocorticoid activity, which carries a potential risk of hyperkalemia (elevated potassium levels). For patients considered high-risk due to pre-existing kidney, liver, or adrenal issues, blood levels of potassium are officially recommended for monitoring before and during the first treatment cycle.

Q: Can Drosianne affect the reliability of birth control methods?

A: Drosianne is a method prescribed for preventing pregnancy. Its reliability as a contraceptive depends strictly on taking the tablets exactly as directed every day, following the sequential 28-day regimen outlined in the official instructions.

Q: What kind of patient monitoring is required when on Drosianne?

A: Official guidelines focus on the monitoring of serum potassium levels. This is specifically recommended during the first treatment cycle for patients who are considered high risk for developing elevated potassium levels due to existing health conditions or concurrent medication use.

Q: Is there a certain diet I should follow while taking Drosianne?

A: Regulatory labeling identifies the potential for grapefruit juice to interact with the drug. Consuming grapefruit juice may increase the plasma concentrations of the hormonal components in the blood by interfering with the way the body metabolizes the medicine.

Q: Does Drosianne interact with herbal remedies like St. John's wort?

A: Official information indicates that herbal products that are potent inducers of certain liver enzymes, such as CYP3A4, may compromise the drug's effectiveness. These products can decrease the levels of Drosianne's active components in the blood, potentially reducing its therapeutic effect.

Q: What if I'm already taking medication for high blood pressure? Can I still use Drosianne?

A: The potential for elevated potassium (hyperkalemia) requires caution when taking Drosianne with certain blood pressure medications. This specifically includes medicines like ACE inhibitors and Angiotensin-II receptor antagonists, which are listed in the official interaction documents.

Q: Is Drosianne considered a high-risk medication by regulatory bodies?

A: Official safety documents detail the potential for serious, but low-frequency, risks, most notably venous thromboembolic events (VTE). These risks are outlined in the Warnings and Precautions sections of the labeling.

Q: Are there any specific warnings about Drosianne during pregnancy or breastfeeding?

A: Official guidance advises that the medicine must be discontinued immediately if pregnancy occurs. For breastfeeding, regulatory information notes that a small amount of the drug’s components is known to be excreted into breast milk.

Q: What does official guidance say about Drosianne and fertility?

A: The drug’s primary action is the suppression of ovulation, which prevents pregnancy during use. Normal menstrual cycles and fertility are generally expected to return to normal after treatment is stopped.

Q: Is the main purpose of Drosianne to treat symptoms or the underlying cause?

A: The official indications include preventing pregnancy and managing symptoms of certain hormone-related conditions like PMDD and moderate acne. The drug works by modulating specific hormone receptors in the body, which addresses the physiological mechanisms behind these conditions.

Q: Do I need to take Drosianne forever, or can I stop after a while?

A: The duration of use is typically determined by the individual's needs. Use typically continues for as long as the need for pregnancy prevention or management of the approved conditions persists and there are no contraindications to continued use.

Q: Why is Drosianne sometimes prescribed for multiple different health issues?

A: Drosianne is prescribed for multiple approved uses because its active progestin component has three distinct, documented effects on the body: progestogenic (for contraception), anti-mineralocorticoid, and anti-androgenic. These multiple actions allow it to address different hormone-related concerns.

Q: How long does Drosianne stay in your system after stopping treatment?

A: Pharmacokinetic data from official documents indicate that the elimination half-life of drospirenone, one of the active components, is approximately 30 to 40 hours. The half-life refers to the time it takes for half of the drug to be cleared from the body.

Q: Is Drosianne the same as a generic version, or is there a difference?

A: The FDA requires that all approved generic versions of a drug must be bioequivalent to the brand-name product. This means they are required to be bioequivalent and therapeutically equivalent to the brand-name product.

Q: What does the term 'contraindication' mean regarding Drosianne?

A: A contraindication is an official safety constraint listing specific health conditions, such as liver or kidney impairment, that strictly prohibit the use of Drosianne. These constraints are in place because the documented risks for patients with these conditions are deemed too high.

Q: What is the risk of dependence or addiction with Drosianne?

A: Drosianne is classified by regulatory information as a hormonal contraceptive. It is not classified as a controlled substance, and official labeling does not include warnings regarding any risk of dependence or addiction.

Q: What is the process for stopping Drosianne treatment safely?

A: Official guidance indicates that discontinuation of Drosianne involves consulting a healthcare provider. After stopping, the effects of the drug cease, and the original menstrual cycle and fertility are expected to return.

Q: Can Drosianne be split or crushed, or must it be swallowed whole?

A: Official administration instructions for the tablet form state that the tablets must be swallowed whole. Official instructions require that the tablets must be swallowed whole to ensure the intended delivery of the active ingredients.

Q: What is the average duration of treatment with Drosianne?

A: The duration of treatment is determined by the specific indication and the patient's goals. Generally, use continues for as long as the need for pregnancy prevention or management of the approved conditions persists.

Q: Is it possible to have an allergic reaction to Drosianne?

A: Like any medication, an allergic reaction is possible. While official safety documents detail common and serious adverse reactions, severe allergic responses are not listed among the most commonly documented side effects.

Q: When was Drosianne first approved by the FDA or a similar agency?

A: The first combined oral contraceptive product containing the components found in Drosianne (drospirenone and ethinyl estradiol) was approved by the FDA in 2001.

How should Drosianne be stored and disposed of?

The storage and disposal of Drosianne (a Drospirenone-containing product) must strictly follow the official conditions outlined in the regulatory labeling.

Storage Requirements

The product must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with temporary fluctuations allowed between 15 C and 30 C (59 F and 86 F). The tablets must be stored in the original container, protected from both moisture and excessive heat, and must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Drosianne must be disposed of in accordance with local pharmaceutical requirements and must not be thrown away via wastewater or household waste. This environmental precaution is required to properly handle the active substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drosianne found in:

A-Z Index: